IC
ARQT icon

Ikarian Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Ikarian Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-489,642
Closed -$4.55M – 153
2024
Q2 		$4.55M Sell
489,642
-100,000
-17% -$904K 0.79% 32
2024
Q1 		$5.84M Buy
+589,642
New +$4.4M 0.64% 50

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital's ARQT Position: Q3 2024 in Review

Ikarian Capital sold out of Arcutis Biotherapeutics (ARQT) in Q3 2024, closing a stake of 489,642 shares — an estimated $4.55M sold.

Ikarian Capital first reported a position in ARQT in Q1 2024 and held it in 2 quarters. The position peaked at $5.84M in Q1 2024. 188 funds tracked by Wall St. Rank hold ARQT as of Q3 2024.

  • Ikarian Capital reported no remaining Arcutis Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Ikarian Capital sold 489,642 Arcutis Biotherapeutics shares in Q3 2024, an estimated $4.55M.
  • Ikarian Capital first reported a position in Arcutis Biotherapeutics in Q1 2024 and held it in 2 quarters.
  • Ikarian Capital's Arcutis Biotherapeutics position peaked at $5.84M in Q1 2024.
  • 188 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2024.

Based on Ikarian Capital's 13F filing for Q3 2024, filed 14 Nov 2024.